Key result
Letermovir provides primary prophylaxis against cytomegalovirus infection in two children.
Key points are not available for this paper at this time.
Population
Two children
Design
Other
Level 5 evidence warrants caution before clinical use; leaves open need for confirmatory trials in hematology.
Sciendo provides publishing services and solutions to academic and professional organizations and individual authors. We publish journals, books, conference proceedings and a variety of other publications.
No takes yet. Share an insight, caveat, or question.
Styczyński et al. (2020) studied this question. Primary prophylaxis with letermovir was used for the prevention of cytomegalovirus infection in two children.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: